No Data
No Data
Denali Therapeutics(DNLI.US) Director Sells US$68,203.6 in Common Stock
$Denali Therapeutics(DNLI.US)$ Director SATO VICKI L sold 3,080 shares of common stock on Jul 1, 2024 at an average price of $22.14 for a total value of $68,203.6.Source: Announcement What is statemen
Denali Therapeutics(DNLI.US) Director Sells US$678.66K in Common Stock
$Denali Therapeutics(DNLI.US)$ Director Krognes Steve E. sold 30,688 shares of common stock on Jun 13, Jul 1, 2024 at an average price of $22.11 for a total value of $678.66K.Source: Announcement What
Form 144 | Denali Therapeutics(DNLI.US) Director Proposes to Sell 143.04K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Denali Therapeutics(DNLI.US)$ Director VICKI LEE SATO intends to sell 6,160 shares of its common stock on Jul 1, with a total market value of approximately $143.04K.
Form 144 | Denali Therapeutics(DNLI.US) Director Proposes to Sell 696.6K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Denali Therapeutics(DNLI.US)$ Director STEVE KROGNES intends to sell 30,000 shares of its common stock on Jul 1, with a total market value of approximately $696.6K.
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?